Tyra Biosciences
NASDAQ: TYRA $25.82 USD
Clinical-stage precision oncology company developing next-generation FGFR inhibitors, including oral dabogratinib for skeletal dysplasia and urologic cancers, using its proprietary SNÅP discovery platform.
Company Info
Sector:Small Molecule Pharma
Headquarters:Carlsbad, California, United States
Founded:2019
Website:tyra.bio/
Upcoming Milestones & Key Dates
2026-09-10
Clinical Data
Bladder cancer response data reported
Clinical Development Pipeline
Dabogratinib
Target: FGFRDabogratinib
Target: FGFRRecent News
No recent news updates available for this company.
Leadership Team
Todd Harris
CEO